Home > Back to Publisher > Report Information

Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

BioSeeker Group AB
January 30, 2012
1704 Pages - SKU: BIOS6796020

Abstract Table of Contents Related Reports

This report will excel your competitive awareness and decrease your decision making time in managing angiogenesis affecting drug development in cancer. Find out whether you are number one, two or further down the ladder in this highly competitive market. Locate the right drugs to benchmark against and see were others may have succeeded or failed before you.

A large number of drugs, both on the market and in development have angiogenesis affecting properties.This report includes both direct angiogenic targets (angiogenesis-related targets) and indirect angiogenic targets (non-angiogenic targets which nevertheless have angiogenesis effects).

This report comprises defined and up to date development strategies for 252 angiogenesis affecting drugs in oncology within the portfolio of 151 companies world-wide, from Ceased to Marketed. The report extensively analyses their 177 identified drug targets, organized into 170 drug target strategies, and assesses them in 70 cancer indications. BioSeeker has applied its unique drug assessment methodology to stratify the angiogenesis affecting drug pipeline in oncology and discern the level of competition in fine detail.

Major Findings from this report:

The identified competitive landscape of angiogenesis affecting drugs in cancer is split between the half which have unique drug target strategies and the other half which have head-to-head target competing drugs in 44 different clusters. The latter has a competing ratio which is almost two times higher than the comparable average of the angiogenesis affecting drugs in general.
Eight out of every ten drug target strategies in Phase III development are new to angiogenesis affecting drugs, whereas only five out of every ten target strategies in Phase II are new.
The greatest number of new target strategies are found in Preclinical (21%) and Phase II (18%) development.
Small molecules, Antibodies and Proteins drugs are the dominating compound strategies of angiogenesis affecting cancer drugs, which represent almost 80% of the entire pipeline.
Protein based angiogenesis affecting cancer drugs has the highest cross-over of drug target strategies with other compound strategies, especially with that of Antibodies and Gene therapies.
Angiogenesis affecting drugs are experiencing targeting competition in five out of every ten cancer indications described, and more so in colorectal cancer, breast cancer and non-small cell lung cancer..
The highest number of described target strategies among angiogenesis affecting drugs are found in colorectal cancer, breast cancer, non-small cell lung cancer and ovarian cancer.
The highest number of described drug target strategies of angiogenesis affecting drugs belongs to Pfizer, Novartis, Abbott, Eli Lilly, EntreMed and Exelixis.

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:

Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties
Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
Supporting development of integrative molecule, pathway and disease area strategies
Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for any angiogenesis affecting drug in cancer to ensure that the optimal market conditions exist by the time the product is commercialized.

1 Executive Summary
2 About Cancer Highlights™: 2.1 Cancer Focus Areas; 2.2 Subscribe Today and Start Saving; 2.3 Additional Information; 2.4 BioSeeker Group’s Oncology Team
3 Methodology: 3.1 Cancer Highlights’™ Five Pillar Drug Assessment
4 Table of Contents: 4.1 List of Figures; 4.2 List of Tables
5 Introduction: 5.1 The Scope of this Report; 5.2 Definitions; 5.3 Abbreviations
6 Consider the Therapeutic Target Among Angiogenesis Affecting Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment: 6.1 Drug Repositioning in Oncology; 6.2 Introduction to Targets of Angiogenesis Affecting Drugs in Oncology; 6.3 The Cancer Genome Project and Targets of Angiogenesis Affecting Drugs in Oncology; 6.4 Angiogenesis Affecting Therapeutics is Stimulated by Available Structure Data on Targets; 6.5 Target-Target Interactions among Identified Targets of Angiogenesis Affecting Drugs in Oncology; 6.6 The Drug-Target Competitive Landscape; 6.7 Protein Expression Levels of Identified Targets of Angiogenesis Affecting Drugs in Oncology; 6.8 Pathway Assessment of Angiogenesis Affecting Drugs in Oncology
7 Emerging New Products to Established Ones: Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology by their Highest Stage of Development: 7.1 Pre-registration to Marketed: New and Unique Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology; 7.2 Phase III Clinical Development: New and Unique Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology; 7.3 Phase II Clinical Development: New and Unique Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology; 7.4 Phase I Clinical Development: New and Unique Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology; 7.5 Preclinical Development: New and Unique Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology; 7.6 Drug Target Strategies of No Data, Suspended or Terminated Angiogenesis Affecting Drugs in Oncology; 7.7 Target Strategy Development Profiles of Angiogenesis Affecting Drugs in Oncology; 7.8 The Competition Through Close Mechanistic Approximation of Angiogenesis Affecting Drugs in Oncology
8 Compound Strategies at Work: Competitive Benchmarking of Angiogenesis Affecting Cancer Drugs by Compound Strategy: 8.1 Small Molecules; 8.2 Peptide & Protein Drugs; 8.3 Antibodies; 8.4 Nucleic Acid Therapies; 8.5 Gene Therapy; 8.6 Drug Delivery and Nanotechnology; 8.7 Compound Strategies based on Sub-Cellular Localization of Drug Targets
9 Selecting Indication for Angiogenesis Affecting Drugs in Oncology: 9.1 Acute Lymphocytic Leukemia; 9.2 Acute Myelogenous Leukemia; 9.3 Adrenal Cancer; 9.4 B-cell Lymphoma; 9.5 Basal Cell Cancer; 9.6 Biliary Cancer; 9.7 Bladder Cancer; 9.8 Bone Cancer; 9.9 Brain Cancer; 9.10 Breast Cancer; 9.11 Cancer (general); 9.12 Carcinoid; 9.13 Cervical Cancer; 9.14 Chemopreventative; 9.15 Chronic Lymphocytic Leukemia; 9.16 Chronic Myelogenous Leukemia; 9.17 Chronic Myelomonocytic Leukemia; 9.18 CNS Cancer; 9.19 Colorectal Cancer; 9.20 Endometrial Cancer; 9.21 Fallopian Tube Cancer; 9.22 Fibro Sarcoma; 9.23 Gastrointestinal Cancer (general); 9.24 Gastrointestinal Stomach Cancer; 9.25 Gastrointestinal Stromal Cancer; 9.26 Head and Neck Cancer; 9.27 Hematological Cancer (general); 9.28 Hodgkin's Lymphoma; 9.29 Kaposi's Sarcoma; 9.30 Leiomyo Sarcoma; 9.31 Leukemia (general); 9.32 Lipo Sarcoma; 9.33 Liver Cancer; 9.34 Lung Cancer (general); 9.35 Lymphangioleiomyomatosis; 9.36 Lymphoma (general); 9.37 Mast Cell Leukemia; 9.38 Mastocytosis; 9.39 Melanoma; 9.40 Mesothelioma; 9.41 Myelodysplastic Syndrome; 9.42 Myeloma; 9.43 Nasopharyngeal Cancer; 9.44 Neuroendocrine Cancer (general); 9.45 Neuroendocrine Cancer (pancreatic); 9.46 Neurofibromatosis; 9.47 non-Hodgkin's Lymphoma; 9.48 Non-Small Cell Lung Cancer; 9.49 Oesophageal Cancer; 9.50 Oral Cancer; 9.51 Osteo Sarcoma; 9.52 Ovarian Cancer; 9.53 Pancreatic Cancer; 9.54 Peritoneal Cancer; 9.55 Prostate Cancer; 9.56 Radio/chemotherapy-induced Alopecia; 9.57 Radio/chemotherapy-induced Infection; 9.58 Renal Cancer; 9.59 Sarcoma (general); 9.60 Small Cell Lung Cancer; 9.61 Soft Tissue Sarcoma; 9.62 Solid Tumor; 9.63 Squamous Cell Cancer; 9.64 Synovial Sarcoma; 9.65 T-cell Lymphoma; 9.66 Testicular Cancer; 9.67 Thyroid Cancer; 9.68 Unspecified; 9.69 Vaccine adjunct; 9.70 Waldenstrom's hypergammaglobulinemia
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator: 10.1 Changes in the Competitive Landscape: M&A, Bankruptcy and Name Change; 10.2 Company Facts and Ranking; 10.3 Competitive Fall-Out Assessment; 10.4 Abbott; 10.5 Acceleron Pharma; 10.6 Access; 10.7 Active Biotech; 10.8 Adherex; 10.9 Advantagene; 10.10 Advaxis; 10.11 Advenchen; 10.12 AEterna Zentaris; 10.13 Agennix; 10.14 Aida Pharmaceuticals; 10.15 Alnylam; 10.16 Ambit Biosciences; 10.17 Ambrilia Biopharma; 10.18 Amgen; 10.19 Amphora; 10.20 Angiogen; 10.21 Angiogenex; 10.22 Angstrom Pharmaceuticals; 10.23 Ansaris; 10.24 Antisoma; 10.25 Arana Therapeutics; 10.26 Ariad; 10.27 Arno Therapeutics; 10.28 ArQule; 10.29 Array BioPharma; 10.30 Astellas; 10.31 Astex Therapeutics; 10.32 AstraZeneca; 10.33 Attenuon; 10.34 Austrianova; 10.35 Bayer; 10.36 BioAlliance Pharma; 10.37 BioAxone; 10.38 Biocad; 10.39 Boehringer Ingelheim; 10.40 Bolder BioTechnology; 10.41 Bristol-Myers Squibb; 10.42 BTG; 10.43 Cancer Research Technology; 10.44 CDG Therapeutics; 10.45 Celecure; 10.46 Celera; 10.47 Celgene; 10.48 Cell Therapeutics; 10.49 CellCeutix; 10.50 Cellmid; 10.51 Cephalon; 10.52 ChemoCentryx; 10.53 Chemokine Therapeutics; 10.54 China Sky One Medical; 10.55 Choongwae; 10.56 Circadian Technologies; 10.57 Cue Biotech; 10.58 Curis; 10.59 Cyclacel; 10.60 Cytochroma; 10.61 Deciphera Pharmaceuticals; 10.62 Dendreon; 10.63 Dyax; 10.64 Eisai; 10.65 Eli Lilly; 10.66 EntreMed; 10.67 Exelixis; 10.68 ExonHit Therapeutics; 10.69 Five Prime Therapeutics; 10.70 GammaCan; 10.71 Genmab; 10.72 Gilead Sciences; 10.73 GlaxoSmithKline; 10.74 GlycoGenesys; 10.75 Green Cross; 10.76 Hoffmann-La Roche; 10.77 Hy BioPharma; 10.78 Idera Pharmaceuticals; 10.79 ImClone Systems; 10.80 ImmunoGen; 10.81 ImmuPharma; 10.82 Introgen Therapeutics; 10.83 Isis Pharmaceuticals; 10.84 Johnson & Johnson; 10.85 KAI Pharmaceuticals; 10.86 Karus Therapeutics; 10.87 Kirin Pharma; 10.88 Kringle Pharma; 10.89 Kyowa Hakko Kirin; 10.90 Lee's Pharmaceutical; 10.91 Lorus Therapeutics; 10.92 MAT Biopharma; 10.93 MediGene; 10.94 Merck & Co; 10.95 Merck KGaA; 10.96 Mersana Therapeutics; 10.97 MethylGene; 10.98 Micromet; 10.99 MolMed; 10.100 Morvus Technology; 10.101 NewSouth Innovations; 10.102 Non-industrial Source; 10.103 Novartis; 10.104 Novelix; 10.105 Noxxon; 10.106 Oasmia; 10.107 Onconova; 10.108 OncoTherapy Science; 10.109 Oncothyreon; 10.110 OSI Pharmaceuticals; 10.111 Oxford BioMedica; 10.112 OXiGENE; 10.113 Pepscan Therapeutics; 10.114 PepTx; 10.115 Peregrine Pharmaceuticals; 10.116 Pfizer; 10.117 Pharmacopeia; 10.118 PharmaMar; 10.119 Pharminox; 10.120 Philogen; 10.121 PhiloGene; 10.122 Pierre Fabre; 10.123 Progen; 10.124 Protein Sciences; 10.125 Protgen; 10.126 PTC Therapeutics; 10.127 Receptor BioLogix; 10.128 Regeneron; 10.129 Rexahn; 10.130 Rigel; 10.131 Sanofi; 10.132 Santaris Pharma; 10.133 Scancell; 10.134 SciClone Pharmaceuticals; 10.135 Semafore Pharmaceuticals; 10.136 Shionogi; 10.137 Simcere Pharmaceuticals; 10.138 Spear Therapeutics; 10.139 SRI International; 10.140 Stainwei Biotech; 10.141 SuperGen; 10.142 Switch Pharma; 10.143 SynDevRx; 10.144 Taiho; 10.145 Tau Therapeutics; 10.146 ThromboGenics; 10.147 Tigris Pharmaceuticals; 10.148 ToolGen; 10.149 TopoTarget; 10.150 Tracon Pharmaceuticals; 10.151 UCB; 10.152 VBL Therapeutics; 10.153 Wilex; 10.154 Xerion
11 Disclaimer
12 Drug Index
13 Company Index
4.1 List of Figures: Figure 1: Visualization of Target-Target Interactions among Targets of Angiogenesis Affecting Drugs in Oncology; Figure 2: The Drug-Target Competitive Landscape of Angiogenesis Affecting Drugs in Oncology - Large Cluster; Figure 3: The Drug-Target Competitive Landscape Angiogenesis Affecting Drugs in Oncology - Smaller Clusters; Figure 4: Head-to-Head Targeting Competitive Landscape of Angiogenesis Affecting Drugs in Oncology; Figure 5: Distribution of Compound Strategies among Angiogenesis Affecting Cancer Drugs; Figure 6: Primary Sub-cellular Localization of Drug Targets; Figure 7: Number of Companies per Ranking Level
4.2 List of Tables: Table 1: Cancer Highlights’™ Five Pillar Drug Assessment; Table 2: Breakdown of the Included Angiogenesis Affecting Drug Pipeline in Oncology by Stage of Development; Table 3: Head to Head Target Competition among Angiogenesis Affecting Drugs in Oncology; Table 4: Overview of Drug Target Strategy Themes; Table 5: Terminally Ceased Targets of Angiogenesis Affecting Drugs in Oncology; Table 6: Official Gene Name to Target Profle; Table 7: Targets of Angiogenesis Affecting Drugs in Oncology Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census; Table 8: Identity of Drug Targets with Available Biological Structures; Table 9: Number of Target-Target Interactions among Targets of Angiogenesis Affecting Drugs in Oncology; Table 10: Available Protein Expression Profiles of Angiogenesis Affecting Drug Targets in Oncology; Table 11: Pathway Summary; Table 12: Drug Targets without any Identified Assigned Pathways; Table 13: Pathway Profiles According to BioCarta of Angiogenesis Affecting Drug Targets in Oncology; Table 14: Pathway Profiles According to KEGG of Angiogenesis Affecting Drug Targets in Oncology; Table 15: Pathway Profiles According to NetPath of Angiogenesis Affecting Drug Targets in Oncology; Table 16: Number of Drug Target Strategies by their Highest Developmental Stage and Uniqueness; Table 17: Top Competitive Target Strategies of Angiogenesis Affecting Drugs in Oncology; Table 18: New and Unique Target Strategies of Pre-registration and Marketed Angiogenesis Affecting Drugs in Oncology; Table 19: The Competition Through Close Mechanistic Approximation Between Angiogenesis Affecting Drugs in Oncology in Pre-registration to Marketed; Table 20: New and Unique Target Strategies in Phase III Clinical Development of Angiogenesis Affecting Drugs in Oncology; Table 21: The Competition Through Close Mechanistic Approximation Between Phase III Angiogenesis Affecting Drugs in Oncology; Table 22: New and Unique Target Strategies in Phase II Clinical Development of Angiogenesis Affecting Drugs in Oncology; Table 23: The Competition Through Close Mechanistic Approximation Between Phase II Angiogenesis Affecting Drugs in Oncology; Table 24: New and Unique Target Strategies in Phase I Clinical Development of Angiogenesis Affecting Drugs in Oncology; Table 25: The Competition Through Close Mechanistic Approximation Between Phase I Angiogenesis Affecting Drugs in Oncology; Table 26: New and Unique Target Strategies in Preclinical Development of Angiogenesis Affecting Drugs in Oncology; Table 27: The Competition Through Close Mechanistic Approximation Between Preclinical Angiogenesis Affecting Drugs in Oncology; Table 28: Target Strategies of No Data, Suspended and Terminated Angiogenesis Affecting Drugs in Oncology; Table 29: Connecting Target Strategy with Its Profile Identification Number; Table 30: The Competition Through Close Mechanistic Approximation Among Angiogenesis Affecting Drugs in Oncology; Table 31: Overview of Compound Strategy Competition Among Angiogenesis Affecting Cancer Drugs; Table 32: Overview of the Competitive Landscape of Small Molecule Based Angiogenesis Affecting Cancer Drugs; Table 33: Competitive Comparison of Target Strategies of Small Molecule Angiogenesis Affecting Cancer Drugs; Table 34: Pursued Target Strategies of Small Molecule Drugs Based Angiogenesis Affecting Cancer Drugs; Table 35: Overview of the Competitive Landscape of Peptide Based Angiogenesis Affecting Cancer Drugs; Table 36: Competitive Comparison of Target Strategies of Peptide Based Angiogenesis Affecting Cancer Drugs; Table 37: Pursued Target Strategies of Peptide Based Angiogenesis Affecting Cancer Drugs; Table 38: Overview of the Competitive Landscape of Protein Based Angiogenesis Affecting Cancer Drugs; Table 39: Competitive Comparison of Target Strategies of Protein Based Angiogenesis Affecting Cancer Drugs; Table 40: Pursued Target Strategies of Protein Based Angiogenesis Affecting Cancer Drugs; Table 41: Overview of the Competitive Landscape of Antibody Based Angiogenesis Affecting Cancer Drugs; Table 42: Competitive Comparison of Target Strategies of Antibody Based Angiogenesis Affecting Cancer Drugs; Table 43: Pursued Target Strategies of Antibody Based Angiogenesis Affecting Cancer Drugs; Table 44: Overview of the Competitive Landscape of Nucleic Acid Based Angiogenesis Affecting Cancer Drugs; Table 45: Competitive Comparison of Target Strategies of Nucleic Acid Based Angiogenesis Affecting Cancer Drugs; Table 46: Pursued Target Strategies of Nucleic Acid Based Angiogenesis Affecting Cancer Drugs; Table 47: Vectors in Gene Therapy; Table 48: Overview of the Competitive Landscape of Gene Therapy Based Angiogenesis Affecting Cancer Drugs; Table 49: Competitive Comparison of Target Strategies of Gene Therapy Based Angiogenesis Affecting Cancer Drugs; Table 50: Pursued Target Strategies of Gene Therapy Based Angiogenesis Affecting Cancer Drugs; Table 51:Overview of the Competitive Landscape of Reformulated Angiogenesis Affecting Cancer Drugs; Table 52: Competitive Comparison of Target Strategies of Reformulated Angiogenesis Affecting Cancer Drugs; Table 53: Pursued Target Strategies of Reformulated Angiogenesis Affecting Cancer Drugs; Table 54: Compound Strategies based on Sub-Cellular Localization of Angiogenesis Affecting Cancer Drug Targets; Table 55 Competitive Summary by Cancer Indication of Angiogenesis Affecting Drugs; Table 56: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Acute Lymphocytic Leukemia; Table 57: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Acute Myelogenous Leukemia; Table 58: The Competition through Close Mechanistic Approximation between Acute Myelogenous Leukemia Drugs; Table 59: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Adrenal Cancer; Table 60: The Competition through Close Mechanistic Approximation between Adrenal Cancer Drugs; Table 61: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of B-cell Lymphoma; Table 62: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Basal Cell Cancer; Table 63: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Biliary Cancer; Table 64: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Bladder Cancer; Table 65: The Competition through Close Mechanistic Approximation between Bladder Cancer Drugs; Table 66: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Bone Cancer; Table 67: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Brain Cancer; Table 68: The Competition through Close Mechanistic Approximation between Brain Cancer Drugs; Table 69: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Breast Cancer; Table 70: The Competition through Close Mechanistic Approximation between Breast Cancer Drugs; Table 71: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Cancer (general); Table 72: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Carcinoid; Table 73: The Competition through Close Mechanistic Approximation between Carcinoid Drugs; Table 74: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Cervical Cancer; Table 75: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Chemopreventative; Table 76: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Chronic Lymphocytic Leukemia; Table 77: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Chronic Myelogenous Leukemia; Table 78: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Chronic Myelomonocytic Leukemia; Table 79: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of CNS Cancer; Table 80: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Colorectal Cancer; Table 81: The Competition through Close Mechanistic Approximation between Colorectal Cancer Drugs; Table 82: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Endometrial Cancer; Table 83: The Competition through Close Mechanistic Approximation between Endometrial Cancer Drugs; Table 84: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Fallopian Tube Cancer; Table 85: The Competition through Close Mechanistic Approximation between Fallopian Tube Cancer Drugs; Table 86: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Fibro Sarcoma; Table 87: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Gastrointestinal Cancer (general); Table 88: The Competition through Close Mechanistic Approximation between Gastrointestinal Cancer (general) Drugs; Table 89: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Gastrointestinal Stomach Cancer; Table 90: The Competition through Close Mechanistic Approximation between Gastrointestinal Stomach Cancer Drugs; Table 91: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Gastrointestinal Stromal Cancer; Table 92: The Competition through Close Mechanistic Approximation between Gastrointestinal Stromal Cancer Drugs; Table 93: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Head and Neck Cancer; Table 94: The Competition through Close Mechanistic Approximation between Head and Neck Cancer Drugs; Table 95: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Hematological Cancer (general); Table 96: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Hodgkin's Lymphoma; Table 97: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Kaposi's Sarcoma; Table 98: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Leiomyo Sarcoma; Table 99: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Leukemia (general); Table 100: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Lipo Sarcoma; Table 101: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Liver Cancer; Table 102: The Competition through Close Mechanistic Approximation between Liver Cancer Drugs; Table 103: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Lung Cancer (general); Table 104: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Lymphangioleiomyomatosis; Table 105: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Lymphoma (general); Table 106: The Competition through Close Mechanistic Approximation between Lymphoma Drugs; Table 107: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Mast Cell Leukemia; Table 108: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Mastocytosis; Table 109: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Melanoma; Table 110: The Competition through Close Mechanistic Approximation between Melanoma Drugs; Table 111: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Mesothelioma; Table 112: The Competition through Close Mechanistic Approximation between Mesothelioma Drugs; Table 113: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Myelodysplastic Syndrome; Table 114: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Myeloma; Table 115: The Competition through Close Mechanistic Approximation between Myeloma Drugs; Table 116: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Nasopharyngeal Cancer; Table 117: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Neuroendocrine Cancer (general); Table 118: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Neuroendocrine Cancer (pancreatic); Table 119: The Competition through Close Mechanistic Approximation between Neuroendocrine Cancer (pancreatic) Drugs; Table 120: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Neurofibromatosis; Table 121: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of non-Hodgkin's Lymphoma; Table 122: The Competition through Close Mechanistic Approximation between non-Hodgkin’s Lymphoma Drugs; Table 123: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Non-Small Cell Lung Cancer; Table 124: The Competition through Close Mechanistic Approximation between non-Small Cell Lung Cancer Drugs; Table 125: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Oesophageal Cancer; Table 126: The Competition through Close Mechanistic Approximation between Oesophageal Cancer Drugs; Table 127: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Oral Cancer; Table 128: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Osteo Sarcoma; Table 129: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Ovarian Cancer; Table 130: The Competition through Close Mechanistic Approximation between Ovarian Cancer Drugs; Table 131: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Pancreatic Cancer; Table 132: The Competition through Close Mechanistic Approximation between Pancreatic Cancer Drugs; Table 133: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Peritoneal Cancer; Table 134: The Competition through Close Mechanistic Approximation between Peritoneal Cancer Drugs; Table 135: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Prostate Cancer; Table 136: The Competition through Close Mechanistic Approximation between Prostate Cancer Drugs; Table 137: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Radio/chemotherapy-induced Alopecia; Table 138: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Radio/chemotherapy-induced Infection; Table 139: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Renal Cancer; Table 140: The Competition through Close Mechanistic Approximation between Renal Cancer Drugs; Table 141: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Sarcoma (general); Table 142: The Competition through Close Mechanistic Approximation between Sarcoma (general) Drugs; Table 143: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Small Cell Lung Cancer; Table 144: The Competition through Close Mechanistic Approximation between Small Cell Lung Cancer Drugs; Table 145: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Soft Tissue Sarcoma; Table 146: The Competition through Close Mechanistic Approximation between Soft Tissue Sarcoma Drugs; Table 147: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Solid Tumor; Table 148: The Competition through Close Mechanistic Approximation between Solid Tumor Drugs; Table 149: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Squamous Cell Cancer; Table 150: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Synovial Sarcoma; Table 151: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of T-cell Lymphoma; Table 152: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Testicular Cancer; Table 153: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Thyroid Cancer; Table 154: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Unspecified; Table 155: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Vaccine adjunct; Table 156: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Waldenstrom's hypergammaglobulinemia; Table 157: Competitive Summary by Investigator of Angiogenesis Affecting Drug Development; Table 158: Summary Table of Corporate Changes in the Competitive Landscape of Angiogenesis Affecting Drug Development in Oncology; Table 159: Example of a Competitive Fall-Out Table (Targeting KDR/Modified); Table 160: Abbott's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 161: Acceleron Pharma's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 162: Access’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 163: Active Biotech's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 164: Adherex's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 165: Advantagene's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 166: Advaxis’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 167: Advenchen's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 168: AEterna Zentaris’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 169: Agennix's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 170: Aida Pharmaceuticals’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 171: Alnylam's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 172: Ambit Biosciences’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 173: Ambrilia Biopharma's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 174: Amgen's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 175: Amphora's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 176: Angiogen's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 177: Angiogenex's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 178: Angstrom Pharmaceuticals’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 179: Ansaris’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 180: Antisoma's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 181: Arana Therapeutics’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 182: Ariad's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 183: Arno Therapeutics’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 184: ArQule's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 185: Array BioPharma's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 186: Astellas’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 187: Astex Therapeutics’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 188: AstraZeneca's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 189: Attenuon's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 190: Austrianova's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 191: Bayer's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 192: BioAlliance Pharma's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 193: BioAxone's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 194: Biocad's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 195: Boehringer Ingelheim's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 196: Bolder BioTechnology's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 197: Bristol-Myers Squibb's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 198: BTG's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 199: Cancer Research Technology's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 200: CDG Therapeutics’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 201: Celecure's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 202: Celera's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 203: Celgene's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 204: Cell Therapeutics’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 205: CellCeutix's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 206: Cellmid's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 207: Cephalon's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 208: ChemoCentryx's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 209: Chemokine Therapeutics’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 210: China Sky One Medical's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 211: Choongwae's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 212: Circadian Technologies’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 213: Cue Biotech's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 214: Curis’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 215: Cyclacel's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 216: Cytochroma's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 217: Deciphera Pharmaceuticals’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 218: Dendreon's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 219: Dyax's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 220: Eisai's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 221: Eli Lilly's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 222: EntreMed's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 223: Exelixis’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 224: ExonHit Therapeutics’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 225: Five Prime Therapeutics’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 226: GammaCan's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 227: Genmab's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 228: Gilead Sciences’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 229: GlaxoSmithKline's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 230: GlycoGenesys’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 231: Green Cross’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 232: Hoffmann-La Roche's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 233: Hy BioPharma's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 234: Idera Pharmaceuticals’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 235: ImClone Systems’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 236: ImmunoGen's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 237: ImmuPharma's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 238: Introgen Therapeutics’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 239: Isis Pharmaceuticals’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 240: Johnson & Johnson's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 241: KAI Pharmaceuticals’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 242: Karus Therapeutics’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 243: Kirin Pharma's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 244: Kringle Pharma's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 245: Kyowa Hakko Kirin's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 246: Lee's Pharmaceutical's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 247: Lorus Therapeutics’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 248: MAT Biopharma's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 249: MediGene's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 250: Merck & Co's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 251: Merck KGaA's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 252: Mersana Therapeutics’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 253: MethylGene's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 254: Micromet's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 255: MolMed's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 256: Morvus Technology's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 257: NewSouth Innovations’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 258: Non-industrial source's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 259: Novartis’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 260: Novelix's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 261: Noxxon's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 262: Oasmia's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 263: Onconova's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 264: OncoTherapy Science's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 265: Oncothyreon's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 266: OSI Pharmaceuticals’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 267: Oxford BioMedica's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 268: OXiGENE's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 269: Pepscan Therapeutics’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 270: PepTx's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 271: Peregrine Pharmaceuticals’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 272: Pfizer's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 273: Pharmacopeia's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 274: PharmaMar's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 275: Pharminox's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 276: Philogen's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 277: PhiloGene's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 278: Pierre Fabre's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 279: Progen's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 280: Protein Sciences’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 281: Protgen's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 282: PTC Therapeutics’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 283: Receptor BioLogix's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 284: Regeneron's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 285: Rexahn's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 286: Rigel's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 287: Sanofi's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 288: Santaris Pharma's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 289: Scancell's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 290: SciClone Pharmaceuticals’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 291: Semafore Pharmaceuticals’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 292: Shionogi's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 293: Simcere Pharmaceuticals’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 294: Spear Therapeutics’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 295: SRI International's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 296: Stainwei Biotech's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 297: SuperGen's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 298: Switch Pharma's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 299: SynDevRx's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 300: Taiho's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 301: Tau Therapeutics’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 302: ThromboGenics’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 303: Tigris Pharmaceuticals’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 304: ToolGen's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 305: TopoTarget's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 306: Tracon Pharmaceuticals’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 307: UCB's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 308: VBL Therapeutics’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 309: Wilex's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out; Table 310: Xerion's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out

Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

Share this report

Other tasks

Research Assistance

Related Markets

Drug Discovery Reports

Free Alert Me service